{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T05:15:58Z","timestamp":1761110158582},"reference-count":75,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["SEMERGEN - Medicina de Familia"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.semerg.2016.02.001","type":"journal-article","created":{"date-parts":[[2016,4,3]],"date-time":"2016-04-03T14:20:10Z","timestamp":1459693210000},"page":"318-327","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Dolor en el herpes z\u00f3ster: prevenci\u00f3n y tratamiento"],"prefix":"10.1016","volume":"43","author":[{"given":"G.","family":"Calvo-Mosquera","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Gonz\u00e1lez-Cal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Calvo-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.Y.","family":"Primucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Plamenov-Dipchikov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl","key":"10.1016\/j.semerg.2016.02.001_bib0380","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1586\/erv.10.30","article-title":"Herpes zoster and postherpetic neuralgia","volume":"9","author":"Johnson","year":"2010","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.semerg.2016.02.001_bib0385","first-page":"1075","article-title":"Herpes zoster and Ppsherpetic neuralgia: Prevention and management","volume":"72","author":"Munsey","year":"2005","journal-title":"Am Fam Phys"},{"key":"10.1016\/j.semerg.2016.02.001_bib0390","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1111\/j.1525-1497.2005.0150.x","article-title":"The incidence of herpes zoster in a United States administrative database","volume":"20","author":"Insinga","year":"2005","journal-title":"J Gen Intern Med."},{"issue":"Suppl 1","key":"10.1016\/j.semerg.2016.02.001_bib0395","doi-asserted-by":"crossref","first-page":"s1","DOI":"10.1086\/510206","article-title":"Recommendations for the management of herpes zoster","volume":"44","author":"Dworkin","year":"2007","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.semerg.2016.02.001_bib0400","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1177\/014107689008301007","article-title":"Epidemiology of shingles","volume":"83","author":"Glynn","year":"1990","journal-title":"J R Soc Med"},{"key":"10.1016\/j.semerg.2016.02.001_bib0405","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.4065\/82.11.1341","article-title":"A population-based stury of the incidence and complication retes of herpes zoster vefore zoster vaccine introduction","volume":"82","author":"Yawn","year":"2007","journal-title":"Mayo Clin Proc."},{"key":"10.1016\/j.semerg.2016.02.001_bib0410","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3810\/pgm.2010.01.2103","article-title":"Treatment of the localized pain of posherpetic neuralgia","volume":"122","author":"Paster","year":"2010","journal-title":"Postgrad Med"},{"key":"10.1016\/j.semerg.2016.02.001_bib0415","first-page":"1432","article-title":"Herpes zoster and posherpetic neuralgia: Prevention and management","volume":"83","author":"Fashner","year":"2011","journal-title":"Am Fam Phys"},{"key":"10.1016\/j.semerg.2016.02.001_bib0420","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa051016","article-title":"A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults","volume":"352","author":"Oxman","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semerg.2016.02.001_bib0425","unstructured":"Bajwa ZH, Ortega E. Postherpetic neuralgia [consultado 3 Nov 2015]. Disponible en: http:\/\/www.uptodate.com\/contents\/postherpetic-neuralgia?source=search_result&search=2015+Postherpetic+neuralgia&selectedTitle=1%7E150"},{"key":"10.1016\/j.semerg.2016.02.001_bib0430","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1212\/01.WNL.0000123261.00004.29","article-title":"Risk factors for posherpetic neuralgia in patients with herpes zoster","volume":"62","author":"Jung","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.semerg.2016.02.001_bib0435","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/0304-3959(96)03122-3","article-title":"Pain and its persistence in herpes zoster","volume":"67","author":"Dworkin","year":"1996","journal-title":"Pain"},{"key":"10.1016\/j.semerg.2016.02.001_bib0440","first-page":"690","article-title":"Postherpetic neuralgia","volume":"84","author":"Watson","year":"2011","journal-title":"Am Fam Phys."},{"issue":"Suppl 1","key":"10.1016\/j.semerg.2016.02.001_bib0445","doi-asserted-by":"crossref","first-page":"S76","DOI":"10.1086\/514260","article-title":"Postherpetic neuralgia: Impact of famciclovir, age, rash severity, and acute pain in herpes zoster patients","volume":"178","author":"Dworkin","year":"1998","journal-title":"J infect Dis"},{"key":"10.1016\/j.semerg.2016.02.001_bib0450","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1056\/NEJMcp013211","article-title":"Clinical practice. Herpes zoster","volume":"347","author":"Gnang","year":"2002","journal-title":"N Engl J Med."},{"issue":"10 suppl A","key":"10.1016\/j.semerg.2016.02.001_bib0455","first-page":"51A","article-title":"Preventing herpes zoster and postherpetic neuralgia through vaccination","volume":"56","author":"High","year":"2007","journal-title":"J Fam Pract."},{"key":"10.1016\/j.semerg.2016.02.001_bib0460","first-page":"531","article-title":"Stop shingles in its tracks","volume":"58","author":"Lang","year":"2009","journal-title":"J Fam Pract."},{"key":"10.1016\/j.semerg.2016.02.001_bib0465","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1097\/AJP.0b013e3181eef686","article-title":"A prospective study of the herpes zoster severity of illness","volume":"26","author":"Drolet","year":"2010","journal-title":"Clin J Pain"},{"key":"10.1016\/j.semerg.2016.02.001_bib0470","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/j.jpain.2010.02.020","article-title":"Predictors of postherpetic neuralgia among patients with herpes zoster: A prospective estudy","volume":"11","author":"Drolet","year":"2010","journal-title":"J Pain"},{"key":"10.1016\/j.semerg.2016.02.001_bib0475","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.vaccine.2008.11.077","article-title":"Herpes zoster vaccination among adults aged 60 years or older in the United States, 2007: uptake of the first new vaccine to target seniors","volume":"27","author":"Lu","year":"2009","journal-title":"Vaccine."},{"key":"10.1016\/j.semerg.2016.02.001_bib0480","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1056\/NEJMcp1302674","article-title":"Herpes Zoster","volume":"369","author":"Cohen","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semerg.2016.02.001_bib0485","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1157\/13121106","article-title":"Prevenci\u00f3n de la neuralgia postherp\u00e9tica","volume":"130","author":"L\u00f3pez","year":"2008","journal-title":"Med Clin (Barc)"},{"key":"10.1016\/j.semerg.2016.02.001_bib0490","first-page":"255","article-title":"Does treatment of acute herpes zoster prevent or shorten postherpetic neuralgia? A systematic review of the literature","volume":"49","author":"Alper","year":"2000","journal-title":"J Fam Pract."},{"key":"10.1016\/j.semerg.2016.02.001_bib0495","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1001\/archinte.1997.00440290095010","article-title":"The effect of treating herpes zoster with oral acyclovir in preventing postherpetic neuralgia. A metaanalysis","volume":"157","author":"Jackson","year":"1997","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.semerg.2016.02.001_bib0500","doi-asserted-by":"crossref","unstructured":"Li Q, Chen N, Yang J, Zhou M, Zhoy D, Zhang Q, et al. Antiviral treatment for preventing postherpetic neuralgia. Cochrane Database Syst Rev. 2009; 2: CD006866.","DOI":"10.1002\/14651858.CD006866.pub2"},{"key":"10.1016\/j.semerg.2016.02.001_bib0505","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1128\/AAC.39.7.1546","article-title":"Valacyclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults","volume":"39","author":"Beutner","year":"1995","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1016\/j.semerg.2016.02.001_bib0510","doi-asserted-by":"crossref","first-page":"89","DOI":"10.7326\/0003-4819-123-2-199507150-00002","article-title":"Famciclovir for the treatment of acute herpes zoster: effects on acute disease and postherpetic neuralgia. A randomized, double-blind, placebo-controlled trial","volume":"123","author":"Tyring","year":"1995","journal-title":"Ann Intern med."},{"key":"10.1016\/j.semerg.2016.02.001_bib0515","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0166-3542(03)00064-0","article-title":"Vrivudin Herpes Zoster Study Troup. Oral brivudin in comparison with acyclovir for herpes zoster: a survey study on postherpetic neuralgia","volume":"59","author":"Wassilew","year":"2003","journal-title":"Antiviral Res."},{"key":"10.1016\/j.semerg.2016.02.001_bib0520","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1136\/bmj.39206.571042.AE","article-title":"Herpes zoster","volume":"334","author":"Wareham","year":"2007","journal-title":"BMJ."},{"issue":"1 suppl 1","key":"10.1016\/j.semerg.2016.02.001_bib0525","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1016\/j.jpain.2007.10.008","article-title":"Diagnosis and assessment of pain associated with herpes zoster and postherpetic neuralgia","volume":"9","author":"Dworkin","year":"2008","journal-title":"J Pain."},{"key":"10.1016\/j.semerg.2016.02.001_bib0530","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.pain.2008.12.022","article-title":"A randomized, placebo-controlled trial of oxycodone and gabapenti fon acute pain in herpes zoster","volume":"142","author":"Dworkin","year":"2009","journal-title":"Pain"},{"key":"10.1016\/j.semerg.2016.02.001_bib0535","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/AJP.0b013e3181934276","article-title":"Efficacy and tolerability of gastricretentive gabapentin for the treatment of postherpetic neuralgia: Results of a double-blind, randomized, placebo-controlled clinical trial","volume":"25","author":"Irving","year":"2009","journal-title":"Clin J Pain"},{"key":"10.1016\/j.semerg.2016.02.001_bib0540","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJM199403313301304","article-title":"A randomized trial of acyclovir for 7 days or 21 days with and without prednisolone for treatment of acute herpes zoster","volume":"330","author":"Wood","year":"1994","journal-title":"N Engl J Med."},{"key":"10.1016\/j.semerg.2016.02.001_bib0545","doi-asserted-by":"crossref","first-page":"376","DOI":"10.7326\/0003-4819-125-5-199609010-00004","article-title":"Acyclovir with and without prednisone for the treatment of herpes zoster. A randomized, placebo-controlled trial","volume":"125","author":"Whitley","year":"1996","journal-title":"Ann Intern Med."},{"key":"10.1016\/j.semerg.2016.02.001_bib0550","first-page":"CD005582","article-title":"Corticosteroids for preventing postherp\u00e9tic neuralgia","volume":"12","author":"Chen","year":"2010","journal-title":"Cochrane Database Syst Rev."},{"key":"10.1016\/j.semerg.2016.02.001_bib0555","first-page":"1256","article-title":"Posherpetic nauralgia","volume":"371","author":"Jonhson","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semerg.2016.02.001_bib0560","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/00002508-200209000-00004","article-title":"The lidocaine patch 5% effectively treats all neuropathic pain qualities; results of a randomized double-blind, vehicle-controlled, 3-week efficacy study with use of the neuropathic pain scale","volume":"18","author":"Galer","year":"2002","journal-title":"Clin J Pain"},{"key":"10.1016\/j.semerg.2016.02.001_bib0565","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.jpain.2006.11.005","article-title":"Sequential medication strategies for postherpetic neuralgia: A cost-effectiveness analysis","volume":"8","author":"Smith","year":"2007","journal-title":"J Pain."},{"key":"10.1016\/j.semerg.2016.02.001_bib0570","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.pain.2005.08.013","article-title":"Algorithm for neuropatic pain treatment: An evidence based proposal","volume":"118","author":"Finnerup","year":"2005","journal-title":"Pain."},{"key":"10.1016\/j.semerg.2016.02.001_bib0575","first-page":"36","article-title":"An evidence-based algorithm for the treatment of neuropathic pain","volume":"9","author":"Finnerup","year":"2007","journal-title":"Med Gen Med."},{"key":"10.1016\/j.semerg.2016.02.001_bib0580","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1111\/j.1468-1331.2010.02999.x","article-title":"EFNS guidelines on pharmacological treatment of neuropathic pain","volume":"17","author":"Attal","year":"2010","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.semerg.2016.02.001_bib0585","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.4065\/mcp.2009.0649","article-title":"Recommendations for the pharmacologic management of neuropathic pain: An overview and literature update","volume":"85","author":"Dworkin","year":"2010","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.semerg.2016.02.001_bib0590","first-page":"CD004846","article-title":"Topical lidocaine for the treatment of postherpetic neuralgia","volume":"2","author":"Khaliq","year":"2007","journal-title":"Cochrane Database Syst Rev."},{"key":"10.1016\/j.semerg.2016.02.001_bib0595","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1155\/2007\/730785","article-title":"Pharmacological management of chronic neuropathic pain: Consensus statement and guidelines from the Canadian Pain Society","volume":"12","author":"Moulin","year":"2007","journal-title":"Pain Res Manage"},{"issue":"2 pt 1","key":"10.1016\/j.semerg.2016.02.001_bib0600","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0190-9622(89)70171-7","article-title":"Topical capsaicin treatment of chronic postherpetic neuralgia","volume":"21","author":"Berstein","year":"1989","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.semerg.2016.02.001_bib0605","first-page":"510","article-title":"A randomized vehicle-controlled trial of topical capsaicin in the treatment of postherpetic neuralgia","volume":"15","author":"Watson","year":"1993","journal-title":"Clin Ther"},{"key":"10.1016\/j.semerg.2016.02.001_bib0610","first-page":"384d-f","article-title":"Clinical inquiries: What measures relieve posherpetic neuralgia?","volume":"58","author":"Garroway","year":"2009","journal-title":"J Fam Pract."},{"key":"10.1016\/j.semerg.2016.02.001_bib0615","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1212\/01.WNL.0000140708.62856.72","article-title":"Practice parameter: Treatment of postherpetic neuralgia: An evidence-based report of the Quality Standards Subcommittee or the American Academy of Neurology","volume":"63","author":"Dubinsky","year":"2004","journal-title":"Neurology."},{"key":"10.1016\/j.semerg.2016.02.001_bib0620","first-page":"CD007393","article-title":"Topical capxaicin (high concentration) for chronic neuropatic pain in adults","volume":"2","author":"Derry","year":"2013","journal-title":"Crochane Database Syst Rev"},{"key":"10.1016\/j.semerg.2016.02.001_bib0625","doi-asserted-by":"crossref","first-page":"e164","DOI":"10.1371\/journal.pmed.0020164","article-title":"Analgesic therapy in postherpetic neuralgia: A quantitative systematic review","volume":"2","author":"Hempenstall","year":"2005","journal-title":"PLoS Med"},{"key":"10.1016\/j.semerg.2016.02.001_bib0630","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.pain.2007.08.033","article-title":"Pharmacologic management of neuropathic pain: A evidence-base recommendations","volume":"132","author":"Dworkin","year":"2007","journal-title":"Pain"},{"key":"10.1016\/j.semerg.2016.02.001_bib0635","doi-asserted-by":"crossref","unstructured":"American Geriatrics Society 2012 Beers Criteria Update Expert Panel. American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in olders adults. J Am Geriatr Soc. 2012; 60: 616-31.","DOI":"10.1111\/j.1532-5415.2012.03923.x"},{"key":"10.1016\/j.semerg.2016.02.001_bib0640","first-page":"469","article-title":"Gabapentin enacarbil extended release for the treatment of posherpetic neuralgia in adults","volume":"9","author":"Thomas","year":"2013","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.semerg.2016.02.001_bib0645","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1016\/j.pain.2014.08.014","article-title":"The effect of oxcarbacepine in peripheral neuropathic pain depends on pain phenotype: A randomized, double-blind, placebo-controlled phenotype-stratified study","volume":"155","author":"Demant","year":"2014","journal-title":"Pain"},{"key":"10.1016\/j.semerg.2016.02.001_bib0650","first-page":"1","article-title":"New addiction criteria: Diagnostic challenges persist in treating pain with opioids","volume":"21","author":"Ballantine","year":"2013","journal-title":"IASP Pain Clinical Updates"},{"key":"10.1016\/j.semerg.2016.02.001_bib0655","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jpain.2008.10.008","article-title":"Clinical guidelines for the use of chronic opioid therapy in chronic non cancer pain","volume":"10","author":"Chou","year":"2009","journal-title":"J Pain"},{"key":"10.1016\/j.semerg.2016.02.001_bib0660","first-page":"CD006146","article-title":"Opioids for neuropathic pain","volume":"8","author":"McNicol","year":"2013","journal-title":"Cochrane Database Sys Rev"},{"key":"10.1016\/j.semerg.2016.02.001_bib0665","first-page":"CD003726","article-title":"Tramadol for neuropathic pain","volume":"3","author":"Hollingshead","year":"2006","journal-title":"Cochrane Database Syst Rev."},{"key":"10.1016\/j.semerg.2016.02.001_bib0670","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0304-3959(03)00020-4","article-title":"Tramadol in post-herpetic neuralgia: A randomized, double-bllind, placebo-controlled trial","volume":"104","author":"Boureau","year":"2003","journal-title":"Pain"},{"key":"10.1016\/j.semerg.2016.02.001_bib0675","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1212\/WNL.59.7.1015","article-title":"Opioids versus antidepressants in postherpetic neuralgia; a randomized, placebo-controlled trial","volume":"59","author":"Raja","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.semerg.2016.02.001_bib0680","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/papr.12200","article-title":"Effectivenes and safety of tapentadol prolonger release (PR) versus a combination of tapentadol PR and pregabalina for the management of severe, chronic low back pain with a neuropahic component: A randomized, double-blind, phase 3b study","volume":"15","author":"Baron","year":"2005","journal-title":"Pain Practice"},{"key":"10.1016\/j.semerg.2016.02.001_bib0685","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.clinthera.2014.07.005","article-title":"Practical considerations for the use of tapentadol prolonged release for the management of severe chronic pain","volume":"37","author":"S\u00e1nchez del \u00c1guila","year":"2015","journal-title":"Clin Ther"},{"key":"10.1016\/j.semerg.2016.02.001_bib0690","doi-asserted-by":"crossref","first-page":"51","DOI":"10.5055\/jom.2013.0147","article-title":"Composite measure to assess efficacy\/gastrointestinal tolerability of tapentadol ER versus oxycodone CR for chronic pain: Pooled analysis of randomized studies","volume":"9","author":"Merchant","year":"2013","journal-title":"J Opioid Manag"},{"key":"10.1016\/j.semerg.2016.02.001_bib0695","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.pain.2012.01.015","article-title":"Is treatment of postherpetic neuralgia in the community consistent with evidence-based recommendations?","volume":"153","author":"Dworkin","year":"2012","journal-title":"Pain"},{"key":"10.1016\/j.semerg.2016.02.001_bib0700","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1471-2296-9-26","article-title":"Primary care incidence and treatment of four neuropathic pain conditions: A descriptive study, 2002-2005","volume":"9","author":"Hall","year":"2008","journal-title":"BMC Family Pract"},{"key":"10.1016\/j.semerg.2016.02.001_bib0705","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.pain.2006.01.030","article-title":"Epidemiology and treatment of neuropathic pain: The UK primare care perspective","volume":"122","author":"Hall","year":"2006","journal-title":"Pain"},{"key":"10.1016\/j.semerg.2016.02.001_bib0710","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","article-title":"Grade guidelines 3. Rating the quality of evidence","volume":"64","author":"Balshem","year":"2011","journal-title":"J Clin epidemiol"},{"key":"10.1016\/j.semerg.2016.02.001_bib0715","doi-asserted-by":"crossref","unstructured":"Finnnerup NB, Attal N, Harouzounians S, McNicol E, Baron R, Dworkin RH, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol (Internet) 2015; 14:162-73[acceso 27 Ene 2015]. Disponible en: http:\/\/www.sciencedirect.com\/science\/article\/pii\/S1474442214702510","DOI":"10.1016\/S1474-4422(14)70251-0"},{"key":"10.1016\/j.semerg.2016.02.001_bib0720","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","article-title":"Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults","volume":"372","author":"Lal","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semerg.2016.02.001_bib0725","unstructured":"CDC. Adult immunization schedule. Immunization recommendations, United States-2011 [consultado 16 Nov 2012]. Disponible en: http:\/\/www.cdc.gov\/mmwr\/preview\/mmwrhtml\/mm6004a10.htm"},{"key":"10.1016\/j.semerg.2016.02.001_bib0730","unstructured":"FDA approves Zostavax vaccine to prevent shingles in individuals 50 to 59 years of age. U.S. Food and Drug Administration; March 24, 2011 [consultado 14 mayo 2014]. Disponible en: http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm248390.htm"},{"issue":"Supl 4","key":"10.1016\/j.semerg.2016.02.001_bib0735","first-page":"29","article-title":"Vacunas frente al virus de la varicela zoster","volume":"25","author":"Salleras","year":"2007","journal-title":"Enferm Infecc Microbiol Clin"},{"issue":"RR-5","key":"10.1016\/j.semerg.2016.02.001_bib0740","first-page":"1","article-title":"Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). Prevention of herpes zoster: Recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"57","author":"Harpaz","year":"2008","journal-title":"MMWR Recomm Rep."},{"key":"10.1016\/j.semerg.2016.02.001_bib0745","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1093\/cid\/ciu918","article-title":"Long-term persistence of zoster vaccine efficacy","volume":"60","author":"Morrison","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.semerg.2016.02.001_bib0750","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1182\/blood-2014-04-573048","article-title":"A phase 1\/2 study of an adjuvanted varicella-zoster virus subunit vaccine in autologous hematopoietic cell transplant recipients","volume":"124","author":"Stadtmauer","year":"2014","journal-title":"Blood"}],"container-title":["SEMERGEN - Medicina de Familia"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1138359316000800?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1138359316000800?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T23:55:57Z","timestamp":1655423757000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1138359316000800"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":75,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["S1138359316000800"],"URL":"https:\/\/doi.org\/10.1016\/j.semerg.2016.02.001","relation":{},"ISSN":["1138-3593"],"issn-type":[{"value":"1138-3593","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dolor en el herpes z\u00f3ster: prevenci\u00f3n y tratamiento","name":"articletitle","label":"Article Title"},{"value":"SEMERGEN - Medicina de Familia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semerg.2016.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Sociedad Espa\u00f1ola de M\u00e9dicos de Atenci\u00f3n Primaria (SEMERGEN). Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}